Takeda Oncology
Tommy Fossen is an accomplished professional with extensive experience in the pharmaceutical and biotech industries, currently serving as the National Account Director for Market Access at Takeda Oncology since January 2024. Previous roles include Director of National Accounts at Lexicon Pharmaceuticals, where engagement with national and regional payers was a key focus, and National Account Director at Amplity Health, collaborating with managed care organizations on a new antifungal product. Tommy's career also encompasses positions as National Account Manager at Syneos Health Commercial Solutions and National Account Manager at Rare Disease Therapeutics, where the direct market access strategy for orphan drugs was emphasized. Earlier roles include District Sales Manager at Horizon Pharma, Regional Sales Manager at Astellas Pharma, and Hospital Account Manager at both Astellas Pharma and Elan Pharmaceuticals. Tommy holds a BA in Business Administration from Baldwin Wallace University and has pursued further education at Louisiana State University and the University of Colorado Colorado Springs.
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.